MedTrace Logo

The Effect of n-3 Polyunsaturated Fatty Acid Supplements in Patients With Non-alcoholic Fatty Liver Disease

NCT00819338 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2012-07-04

No results posted yet for this study

Summary

The principal purpose of this study is to determine whether increased intakes of n-3 polyunsaturated (omega-3) fatty acids will reduce the amount of fat stored in the liver in patients with non-alcoholic fatty liver disease.

Conditions

  • Non-alcoholic Fatty Liver Disease

Interventions

DIETARY_SUPPLEMENT

Efamax

5g daily as capsules for 3 months

Sponsors & Collaborators

  • University of Nottingham

    lead OTHER

Principal Investigators

  • Ian A Macdonald, PhD · Biomedical Sciences, University Hospital, Nottingham

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00819338 on ClinicalTrials.gov